Publicacións en colaboración con investigadores/as de Instituto de Investigación Sanitaria del Hospital Universitario La Paz (22)

2024

  1. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

    Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

  2. Evaluation of the transition from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease

    Gastroenterologia y Hepatologia

  3. Human intestinal spirochetosis: an entity associated with sexual transmitted infections

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 42, Núm. 5, pp. 231-235

  4. Selective granulocyte–monocyte apheresis during induction with vedolizumab in moderate–severe ulcerative colitis: Experience in a tertiary hospital

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 721-726

  5. Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients

    Inflammatory Bowel Diseases, Vol. 30, Núm. 2, pp. 167-182

  6. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

    Pharmaceutics, Vol. 16, Núm. 5

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Current management of bowel failure due to Crohn's disease in Spain: Results of a GETECCU survey

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 6, pp. 439-445

  3. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  4. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  5. Influence of biologic therapy on cardiovascular risk factors in patients with inflammatory bowel disease

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 109-115

  6. Randomized clinical trial evaluating three low-volume preparations for colonoscopy in outpatients with Inflammatory Bowel Disease: the EII-PREP trial

    Scandinavian Journal of Gastroenterology, Vol. 58, Núm. 6, pp. 656-663

  7. Serologic response to COVID-19 vaccines in patients with inflammatory bowel disease: a prospective study

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 8, pp. 444-449

  8. Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease

    Scientific Reports, Vol. 13, Núm. 1

2022

  1. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Doppler Activity and Ultrasonographic Detection of Intra-Abdominal Fistulas Are Predictors of Surgery in Crohn's Disease

    Digestive Diseases, Vol. 39, Núm. 3, pp. 204-210

  2. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2020

  1. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry

    Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616

  2. Is the degree of i2a recurrence in Crohn's disease secondary to ischemic phenomena?

    Revista Espanola de Enfermedades Digestivas, Vol. 113

  3. Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey

    Inflammatory bowel diseases, Vol. 26, Núm. 8, pp. 1149-1154